Antimicrobial Agents and Chemotherapy · 1993 · 67 citations · 17 references
Life SciencesInfectious DiseasesMicrobiologyGlycobiologyMedical MicrobiologyMicrobial PathogenesisMicrobial GlycobiologyResistance In Gram-positive BacteriaGlycopeptide AntibioticsPathogenic Effects
Rifampin was glycosylated by a pathogenic species of Nocardia, i.e., Nocardia brasiliensis. The structures of two glycosylated compounds (RIP-1 and RIP-2) isolated from the culture broth of the bacterium were determined to be 3-formyl-23-(O-[beta-D-glucopyranosyl])rifamycin SV and 23-(O-[beta-D-glucopyranosyl])rifampin, respectively. Both compounds lacked antimicrobial activity against other gram-positive bacteria as well as the Nocardia species.
17
Raoul Ė. Benveniste, Julian Davies · Proceedings of the National Academy of Sciences · 1973 · 507 citations · Full text
Rifampicin: A New Orally Active Rifamycin
N. Maggi, C.R. Pasqualucci, R Ballotta et al. · Chemotherapia · 2009 · 267 citations
T.G. Walker, Robert E. London, Thomas W. Whaley et al. · Journal of the American Chemical Society · 1976 · 182 citations
Pharmacy, Biochemistry, Chemistry +17